
Verdiva Bio completes enrolment for oral GLP-1 trial
Biopharmaceutical company Verdiva Bio has completed its participant enrolment for the Phase IIb study of its once-weekly oral GLP-1. VRB-101 is a once-weekly oral, cAMP-biased, GLP-1 peptide analogue candidate for body weight reduction in people with overweight or obesity. The Phase IIb EVOLVE-2 trial is randomised, double-blind… Read More














